Controlling for the future

Edwards SAPIEN 3 Ultra TAVR facilitates future coronary access



Edwards

You're always thinking ahead. We can get behind that.

Your first-time valve choice today affects your patients' treatment options tomorrow.

PARTNER 1A4

n=348

Up to 75% of severe aortic stenosis patients are at risk of developing CAD* requiring future coronary intervention.¹ Prevalence of CAD in TAVR patients Intermediate-Risk High-Risk Low-Risk 73 years old 82 years old 84 years old 74.9% 69.6% 27.7%


PARTNER 2 S3i³

n=1.077

Future intervention may be performed under limited TAVR experience.⁵ 2 out of 3 PCI centers do not have a TAVR program⁵ >60% of the population over the age of 65 live closer to a PCI-only center⁵

The design of the SAPIEN 3 valves is associated with favorable coronary access post-TAVR⁶ and post-TAVR-in-TAVR.⁷

The SAPIEN 3 Ultra valve facilitates future coronary access with low frame height, intra-annular leaflets, and large open cells.



Planning for future coronary access starts with Edwards SAPIEN 3 Ultra TAVR today

*Coronary Artery Disease

PARTNER 32

Preserve future treatment options by choosing Edwards SAPIEN 3 Ultra TAVR today. Your Higher Standard.

- 1. Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. *J Am Coll Cardiol*. 2018;71(12):1360-1378.
- 2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med*. 2019;380(18):1695-1705.
- 3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609-1620.
- 4. Leon MB, Smith CR, Mack MJ, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010;363(17):1597-1607.
- 5. 2017 ACS Census Data, 2018 Medicare Quarterly SAF.
- 6. Ochiai T, Chakravarty T, Yoon SH, et al. Coronary access after TAVR. JACC Cardiovasc Interv. 2020;13(6):693-705.
- 7. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. *JACC Cardiovasc Interv.* 2020; 13(21):2528-2538.
- 8. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. *Circ Cardiovasc Interv.* 2020;13:e008972. DOI: 10.1161/CIRCINTERVENTIONS.120.008972

CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--US-4357 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com

